Clinical Trials Using Palifermin
Clinical trials are research studies that involve people. The clinical trials on this list are studying Palifermin. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients with High-Risk Multiple Myeloma
This phase I / II trial studies the side effects and best dose of melphalan and total marrow irradiation and how well they work with autologous stem cell transplantation in treating patients with high-risk multiple myeloma. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Total marrow irradiation is a type of radiation therapy and a form of total body irradiation that may deliver focused radiation to the major marrow sites where cancer cells reside. Giving chemotherapy and total-body irradiation before a peripheral autologous blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase I / II trial studies the side effects and best dose of palifermin and to see how well it works in preventing graft-versus-host disease in patients with hematologic malignancies undergoing donor stem cell transplant. Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving palifermin before the transplant may stop this from happening.
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Palifermin with Leuprolide Acetate after Total-Body Irradiation Based Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
This phase II trial studies how well giving palifermin with leuprolide acetate works after total body-irradiation based donor stem cell transplant in treating patients with hematologic malignancies. Giving chemotherapy and total body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving palifermin and leuprolide acetate and removing the T cells from the donor cells before transplant may stop this from happening. It is not yet known whether giving palifermin with leuprolide is more effective in helping the immune system recover faster after a donor stem cell transplant.
Location: Memorial Sloan-Kettering Cancer Center, New York, New York